| Characteristic | Schober 2001 | Tunbridge 1989 | Zinman 1999 | Rossetti 2003 | Vague 2003 | 
| Intervention 1 (I1) / intervention 2 (I2) / control 1 (C1) | I1: Glargine + HI C1: NPH + HI | I1: Ultralente + HI C1: Lente + HI | I1: Ultralente + Lispro C1: NPH + Lispro | I1: Glargine dinnertime + Lispro I2: Glargine bedtime + Lispro C: NPH + Lispro | I1: Detemir + Aspart C: NPH + Aspart | 
| [n] (I1/ I2 / C1 / total) | 174/175/349 | 66/66/66 | 87/91/178 | 17/17/17/54 | 301/146/447 | 
| Sex (male) [n,%] | ? | 37, 56% | 41, 47% / 35, 38* | 9, 52% / 8, 47% / 10, 58% | 162, 53% / 74, 50.7% | 
| Age [years] mean (SD) | 11.8 (2) / 11.5 (2) | 38 (range 18‐62) | 35 (1) / 35 (1) | 32 (3) / 31.3 (3.4) / 34 (3.1) | 38.9 (13.3) / 41.8 (14.2) | 
| Ethnic groups [%] | ? | ? | ? | ? | ? | 
| Duration of disease [years] mean (SD) | ? | 14 (range 3‐30) | 13.6 (0.8) / 16.1 (1.1) | 13.1 (1.9) / 12.9 (2.3) / 14.8 (2.3) | 17.1 (9.9) / 17.4 (11) | 
| Body mass index [kg/m2] mean (SD) Weight [kg] mean (SD) | 18.8 (2) / 18.9 ( 2) | 25.3 (range 18.6‐33.4) Kg: 73.0 (range 45.6‐99.0) | 25 (1) / 25 (1) Kg: 74 (1) / 75 (1) | 23.1 (0.8) / 22.9 (1) / 23.2 (0.9) | 24.5 (3.2) / 24.6 (3.4) Kg: 71.5 (11.9) / 71.2 (11.5) | 
| Pharmaco‐naive patients [n,%] | 0 / 0 | 0 / 0 | 0 / 0 | 0/0/0 | 0/0/0 | 
| HbA1c [%] mean (SD) | ? (all <12%) | 9.0 (range 6.6‐11.4) | 8.2 (0.1) / 8.2 (0.1) | 6.9 (0.1) / 6.8 (0.2) / 7 (0.2) | 8.18 (1.14) / 8.11 (1.12) | 
| Fasting blood glucose | ? | ? | ? | ? | ? | 
| Fasting plasma glucose | ? | ? | ? | ? | 11.6 (5.21) / 11.6 (5.27) | 
| Basal insulin dose (IU/day) | ? | ? | ? | ? | 27.4 (12.5) / 25.2 (13.7) | 
| Bolus insulin dose (IU/day) | ? | ? | ? | ? | 30.9 (15.5) / 29.6 (15.8) | 
| Clinically different baseline characteristics (Y/N) | N | NA | NA | N | N | 
| Notes | letter publication | crossover trial | |||
| Symbols & abbreviations: Y = yes; N = no; ? = unclear I = intervention; C = control |